## Clinical Context This patient has CKD stage 3b (eGFR 22 mL/min/1.73m²) with diabetic nephropathy, evidenced by significant proteinuria (UACR 450 mg/g) and progressive renal dysfunction in the setting of long-standing diabetes. ## Key Point: **Metformin is contraindicated in CKD stage 3b and beyond** due to the risk of lactic acidosis. At eGFR <30 mL/min/1.73m², metformin accumulates and nephrotoxicity risk escalates. ## High-Yield: **SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)** are now first-line agents in diabetic CKD because they: - Reduce proteinuria independent of glucose control - Slow GFR decline - Reduce cardiovascular and renal mortality - Are safe across all eGFR ranges - Provide cardio-renal protection beyond ACE-I/ARB monotherapy ## Blood Pressure Management **Key Point:** **Target BP <120 mmHg systolic** (not <130 mmHg) is now recommended in CKD with albuminuria by recent guidelines (KDIGO 2021). This patient's BP of 138/88 mmHg is above target and requires intensification. ## Recommended Next Steps (in order) 1. **Discontinue metformin** immediately 2. **Initiate SGLT2 inhibitor** (e.g., empagliflozin 10 mg daily or dapagliflozin 10 mg daily) 3. **Intensify BP control** to <120 mmHg systolic using additional agents if needed (e.g., add amlodipine dose increase or a thiazide-like diuretic) 4. Continue lisinopril (ACE-I is renal-protective and should be maintained) 5. Monitor eGFR and electrolytes 2–4 weeks after initiation ## Why This Approach? ```mermaid flowchart TD A[CKD Stage 3b + Diabetic Nephropathy]:::outcome --> B{Medication review}:::decision B -->|Metformin at eGFR 22| C[CONTRAINDICATED - Lactic acidosis risk]:::urgent B -->|ACE-I/ARB| D[Continue - Renal protective]:::action A --> E{BP target}:::decision E -->|Current 138/88| F[Above target <120 systolic]:::outcome F --> G[Intensify antihypertensive therapy]:::action A --> H[Add SGLT2 inhibitor]:::action H --> I[Slows GFR decline, reduces proteinuria]:::outcome C --> J[Discontinue metformin]:::action G --> K[Recheck BP, eGFR in 2-4 weeks]:::action ``` ## Clinical Pearl: **SGLT2 inhibitors are now considered disease-modifying agents in CKD**, not just glucose-lowering drugs. They should be offered to all CKD patients with diabetes, regardless of baseline HbA1c. [cite:KDIGO 2021 Clinical Practice Guideline for Diabetes Management in CKD] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.